Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Dose-dependent olanzapine-associated leukopenia: three case reports
Autore:
Kodesh, A; Finkel, B; Lerner, AG; Kretzmer, G; Sigal, M;
Indirizzi:
Lev Hasharon Mental Hlth Med Ctr, IL-42100 Netanya, Israel Lev Hasharon Mental Hlth Med Ctr Netanya Israel IL-42100 Netanya, Israel
Titolo Testata:
INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY
fascicolo: 2, volume: 16, anno: 2001,
pagine: 117 - 119
SICI:
0268-1315(200103)16:2<117:DOLTCR>2.0.ZU;2-Q
Fonte:
ISI
Lingua:
ENG
Soggetto:
CLOZAPINE-INDUCED AGRANULOCYTOSIS; RISPERIDONE; SCHIZOPHRENIA; SAFE;
Keywords:
agranulocytosis; atypical antipsychotics; blood dyscrasias; dose-dependent leukopenia; leukopenia; neutropenia; olanzapine;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Life Sciences
Citazioni:
16
Recensione:
Indirizzi per estratti:
Indirizzo: Kodesh, A Lev Hasharon Mental Hlth Med Ctr, POB 90 000, IL-42100 Netanya, Israel Lev Hasharon Mental Hlth Med Ctr POB 90 000 Netanya Israel IL-42100
Citazione:
A. Kodesh et al., "Dose-dependent olanzapine-associated leukopenia: three case reports", INT CLIN PS, 16(2), 2001, pp. 117-119

Abstract

Leukopenia and agranulocytosis are well reported and dangerous haematological side-effects associated with the use of typical and atypical antipsychotics. These potentially life-threatening phenomena have led to treatment discontinuation and the consequent reemergence of psychiatric symptoms. We report three cases of patients who developed leukopenia during olanzapine treatment. In each case, the leukopenia was dose-dependent. Reduction in the dose of olanzapine was followed by normalization of the white blood count which allowed continuation of the medication. These cases suggest the possibility that, in some patients, leukopenia or agranulocytosis during olanzapine treatment might be dose-related. Thus, olanzapine dose reduction may permit treatment continuation where this is clinically indicated. In our cases,haematological side effects were satisfactorily controlled by dose reduction without allowing the reemergence of psychiatric symptoms. This clinical management may offer an alternative to treatment suspension. A careful monitoring of the white blood count is obviously recommended. Olanzapine may beconsidered a potential and safer treatment for a this specific group of patients. (C) 2001 Lippincott Williams & Wilkins.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 23/01/20 alle ore 12:23:20